Application of International Consensus Meeting Criteria for Classifying Drug-Induced Liver Disorders

Bussières, Jean-François; Habra, Magdi

doi:10.1177/106002809502900910

Cited by 10 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…28 Because the nine patients with liver damage in our study had undergone chemotherapy using other anticancer drugs (eg, CDDP) without any adverse events beyond grade 3, it is unclear whether these anticancer drugs affected the liver enzyme levels. Gefitinib is metabolized by CYP3A4 and is O-demethylated by CYP2D6 in the liver.…”

Section: Discussionmentioning

confidence: 99%

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Sugiura¹,

Nemoto²,

Kawai³

et al. 2013

LCTT

View full text Add to dashboard Cite

Background: Gefitinib is known as one of the agents for treating patients with both advanced lung cancer and an epidermal growth-factor receptor mutation. In the epidermal growth-factor receptor-mutant advanced non-small-cell lung cancer population, gefitinib therapy has been associated with increased response rate, longer progression-free survival, and better quality of life compared to other anticancer drugs. However, gefitinib has to be discontinued for patients in whom adverse events occur, even if it is still effective. Here, we retrospectively assessed the clinical course of patients receiving gefitinib therapy, with a particular focus on liver damage. Patients and methods: Of 24 Asian patients treated with 250 mg gefitinib daily at Kanagawa National Hospital, Japan, between January 2008 and June 2012, grade 3 liver damage (Common Terminology Criteria for Adverse Events, version 4.0) occurred in nine and were eligible for our assessment. The regimen was subsequently changed to alternate-day administration. The relationships between liver damage and each clinical factor were retrospectively examined using Fisher's exact test. Results: Of the nine patients with liver damage, seven had previous exposure to another anticancer drug. There was a significant relationship between the incidence of liver damage and previous chemotherapy (P = 0.009). The objective response rates of patients treated with daily gefitinib 250 mg and alternate-day gefitinib following liver damage were 66.7% and 46.7%, respectively; these were not significantly different (P = 0.597). Conclusion: Gefitinib for advanced adenocarcinoma patients who have previously undergone chemotherapy should be used cautiously and liver function monitored closely, because it frequently induces significant liver damage. The alternate-day administration of gefitinib may be a suitable option for patients in whom daily gefitinib therapy induces liver damage.

show abstract

Section: Discussionmentioning

confidence: 99%

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Sugiura¹,

Nemoto²,

Kawai³

et al. 2013

LCTT

View full text Add to dashboard Cite

show abstract

“…It is less suggestive if this decrease occurs during a period of 30 days from withdrawing the offending drug. In the case of elevated alkaline phosphatase (ALP) or total bilirubin, a decrease of 50% within 6 months is suggestive of DILI of cholestatic type [8,10,11,15]. The diagnosis of DILI is frequently overlooked for several reasons.…”

Section: Establishing the Diagnosismentioning

confidence: 99%

“…Predominant elevation of transaminases favors hepatocellular death, whereas bile duct damage is evidenced by an increase in alkaline phosphatase levels. When neither laboratory values predominate, the type of hepatic injury is ambiguous and is classified as a mixed pattern [8,16].…”

Section: Clinical and Histologic Featuresmentioning

confidence: 99%

See 1 more Smart Citation

Drug-Induced Liver Injury: Review Article

et al. 2007

View full text Add to dashboard Cite

“…These are then commonly used to assess the possible health risk in humans [22]. The liver is a metabolically active organ responsible for many vital life functions, some of such primary functions include; bile production and excretion; excretion of bilirubin, cholesterol, hormones, and drugs; metabolism of fats, proteins, and carbohydrates; storage of glycogen, vitamins, and minerals; synthesis of plasma proteins, such as albumin, and clotting factors, as well as blood detoxification and purification [23]. Due to these important activities, the liver is one of the body's organs most subject to injury.…”

Section: Discussionmentioning

confidence: 99%

Sub-acute toxicological effects of Jobelyn® on pregnant albino rats

Adebayo¹,

Yakubu²,

Egbung³

et al. 2018

AIP Conference Proceedings

View full text Add to dashboard Cite

Abstract. The aim of the present study was to investigate the sub-acute toxicological effects of Jobelyn ® on pregnant albino rats by employing biochemical, haematological and histopathological methods. A total of 32 pregnant female rats were randomly assigned to four different groups of eight rats each. The control group received distilled water and different doses of Jobelyn ® ; 250, 500, 1000 mg kg -1 were administered orally once a day for 2 weeks to the other groups. Biochemical analysis revealed a significant decrease (p<0.05) in the levels of alanine aminotransferase, albumin, urea, PCV and Hb in the treatment groups when compared to the control. However, the significant decrease in PCV and Hb was observed solely in the group treated with 1000 mg kg -1 body weight, suggesting that this decrease could be dosedependent. Alkaline phosphatase, total protein, triglycerides, cholesterol, HDL cholesterol, LDL cholesterol, eosinophils, basophils, neutrophils, monocytes, lymphocytes, WBC count, revealed no significant difference (p<0.05) when compared to the control. The results show that at an appropriate dosage, the use of Jobelyn ® during pregnancy may have no adverse effect on the liver and kidney tissues and may possess hepatoprotective and nephroprotective properties however the histopathological studies revealed that very high levels of Jobelyn may be hepatotoxic.

show abstract

Application of International Consensus Meeting Criteria for Classifying Drug-Induced Liver Disorders

Cited by 10 publications

References 15 publications

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy

Drug-Induced Liver Injury: Review Article

Sub-acute toxicological effects of Jobelyn® on pregnant albino rats

Contact Info

Product

Resources

About